1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Kaleido Biosciences, Inc.
  6. Summary
    KLDO   US4833471000

KALEIDO BIOSCIENCES, INC.

(KLDO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Otc Markets
05/09/2022 05/10/2022 05/11/2022 05/12/2022 05/13/2022 Date
0.08(c) 0.082(c) 0.065(c) 0.061(c) 0.062(c) Last
403 378 658 323 488 809 268 808 1 087 475 Volume
-15.65% +2.50% -20.73% -6.15% +1.64% Change
More quotes
Estimated financial data (e) (USD)
More Financials
Company
Kaleido Biosciences, Inc. is a clinical-stage healthcare company that is focused on microbiome organs to treat disease and improve human health. The CompanyÔÇÖs product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. It is advancing a pipeline of MMT candidates to... 
More about the company
Ratings of Kaleido Biosciences, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about KALEIDO BIOSCIENCES, INC.
04/20KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from S&P Global BMI Index
CI
04/20KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from S&P TMI Index
CI
04/15KALEIDO BIOSCIENCES, INC.(NASDAQGS : KLDO) dropped from NASDAQ Composite Index
CI
04/14Top Premarket Gainers
MT
04/14CAPITALGAINSREPORT : Must See Healthcare Stocks Under $1 (WHSI, KLDO, AGRX, PTE, AKBA)
AQ
04/13Top Premarket Gainers
MT
04/08Top Midday Decliners
MT
04/08Kaleido Biosciences Ceases Operations, Will Delist From Nasdaq; Shares Fall
MT
04/08KALEIDO BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
AQ
04/08Kaleido Biosciences, Inc. Announces Management Changes
CI
04/08Kaleido Biosciences, Inc. Announces Cessation of All of the Company’s Ongoing Oper..
CI
04/04Chardan Cuts Kaleido Biosciences to Neutral From Buy, PT to $1.70 From $3 After Securit..
MT
04/04Kaleido Biosciences Initiated Process to Explore Strategic Alternatives
CI
04/01Kaleido Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31,..
CI
04/01KALEIDO BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
More news
News in other languages on KALEIDO BIOSCIENCES, INC.
04/08Kaleido Biosciences, Inc. annonce la cessation de toutes les opérations en cours de la ..
04/08Kaleido Biosciences, Inc. annonce des changements de direction
04/04Kaleido Biosciences a lancé un processus d'exploration d'alternatives stratégiques
04/01Kaleido Biosciences, Inc. annonce ses résultats pour l'année complète se terminant le 3..
04/01Kaleido Biosciences, Inc. L'auditeur émet des doutes sur la pérennité de l'entreprise
More news
Analyst Recommendations on KALEIDO BIOSCIENCES, INC.
More recommendations
Chart KALEIDO BIOSCIENCES, INC.
Duration : Period :
Kaleido Biosciences, Inc. Technical Analysis Chart | KLDO | US4833471000 | MarketScreener
Technical analysis trends KALEIDO BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 0,06
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Theo Melas-Kyriazi Chairman
Kimberly Hocknell Senior Vice President-Technical Operations
Alison Long Chief Medical Officer
Mark Wingertzahn Head-Development, SVP-Research & Development
Bonnie L. Bassler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
KALEIDO BIOSCIENCES, INC.-97.41%3
MODERNA, INC.-45.70%54 855
LONZA GROUP AG-27.63%40 862
IQVIA HOLDINGS INC.-26.03%39 504
SEAGEN INC.-12.27%24 966
ICON PUBLIC LIMITED COMPANY-31.87%17 153